| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 2.3MM | +10% |
| Gross Profit | 1.5MM | +0% |
| Cost Of Revenue | 750.9K | +35% |
| Operating Income | -2MM | +31% |
| Operating Expenses | 3.5MM | +16% |
| Net Income | -1.9MM | +32% |
| R&D | 176.9K | +4% |
| G&A | 3.3MM | +17% |
| Amortization | 12.1K | -24% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
PRC Alliance Pain Relief Center operates 8 locations across central Florida Dr. Bakshi reports 100% success performing Epidural Steroid Injection (ESI) procedures during evaluation period ROSELAND, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has commenced sales of CompuFlo® Epidural disposables into PRC Alliance Pain Relief Center
Reports acceleration of reimbursement claims submission for the CompuFlo® Epidural System TechnologyROSELAND, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provides a business update and announces financial results for the year ending December 31, 2023. Arjan Haverhals, CEO and President of Milestone Scientific, stated, “We achieved solid financial
ROSELAND, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Monday, April 1, 2024, to discuss the company’s financial results for 2023, as well as the company’s corporate progress and other developments The conference call will be available via telephone by dialing toll free 888-50
Follows successful evaluation by Omaha Pain Physicians’ founder and medical director, Dr. Matthew Stottle, reporting 100% successROSELAND, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has commenced sales of CompuFlo® Epidural disposables to Omaha Pain Physicians, a comprehensive medical pain management center in Omaha, NE. Omaha Pa
ROSELAND, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announces it has commenced direct sales of its STA Single Tooth Anesthesia System® (STA) with Meridian Endo & Perio, a large endodontics, periodontics and implant dentistry practice with three offices in Wisconsin. Dr. Lisa Teel, periodontist and implant surgeon with Meridian Endo and Perio, stat
ROSELAND, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announces it has commenced sales of its STA Single Tooth Anesthesia System® (STA) with Maine Dental Group, a premier group of 21 dental practices across the northeastern United States. Arjan Haverhals, Chief Executive Officer of Milestone Scientific, noted, “We are honored to add Maine Dental Gro
Reports initial reimbursements of CompuFlo® by commercial payors and MedicareROSELAND, N.J., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided the following letter to shareholders from the Company’s CEO, Arjan Haverhals, including updates regarding commercialization of the CompuFlo® technology and initial reimbursements of CompuFlo by commercial payors
ROSELAND, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the closing of its previously announced underwritten public offering of 4,765,000 shares of its common stock at a public offering price of $0.63 per share (the “Offering”). Gross proceeds before deducting underwriting discounts, commissions and other Offering expenses were approximately
ROSELAND, N.J., Dec. 10, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the pricing of an underwritten public offering of 4,765,000 shares of its common stock at a price of $0.63 per share (the “Offering”). Gross proceeds before underwriting discounts and commissions and estimated Offering expenses are expected to be approximately $3.0 million. The Offering
ROSELAND, N.J., Dec. 08, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has commenced an underwritten public offering of shares of its common stock (the “Offering”). The Company also expects to grant to the underwriters a 45-day option to purchase up to an additional 15% of the shares of common stock offered in the Offering on the same terms and con